China Biologic Products Inc (CBPO) : Baring Asset Management Ltd scooped up 2,500 additional shares in China Biologic Products Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 25, 2016. The investment management firm now holds a total of 131,284 shares of China Biologic Products Inc which is valued at $15,452,127.China Biologic Products Inc makes up approximately 1.22% of Baring Asset Management Ltd’s portfolio.
Other Hedge Funds, Including , Daiwa Securities Group added CBPO to its portfolio by purchasing 500 company shares during the most recent quarter which is valued at $58,850.Hermes Investment Management Ltd boosted its stake in CBPO in the latest quarter, The investment management firm added 53,214 additional shares and now holds a total of 266,727 shares of China Biologic Products Inc which is valued at $29,510,675. China Biologic Products Inc makes up approx 0.58% of Hermes Investment Management Ltd’s portfolio. Palo Capital added CBPO to its portfolio by purchasing 3,600 company shares during the most recent quarter which is valued at $398,304. China Biologic Products Inc makes up approx 0.13% of Palo Capital’s portfolio.Copper Rock Capital Partners boosted its stake in CBPO in the latest quarter, The investment management firm added 10,560 additional shares and now holds a total of 20,960 shares of China Biologic Products Inc which is valued at $2,313,984. China Biologic Products Inc makes up approx 0.17% of Copper Rock Capital Partners’s portfolio.Bnp Paribas Arbitrage Sa reduced its stake in CBPO by selling 14,174 shares or 99.72% in the most recent quarter. The Hedge Fund company now holds 40 shares of CBPO which is valued at $4,656.
China Biologic Products Inc closed down -2.22 points or -1.83% at $119.38 with 2,35,500 shares getting traded on Friday. Post opening the session at $121.65, the shares hit an intraday low of $118.67 and an intraday high of $121.65 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
On the company’s financial health, China Biologic Products Inc reported $1.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.21 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.88. The company had revenue of $85.60 million for the quarter.The company’s revenue was up 21.6% compared to the same quarter last year.
China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).